Literature DB >> 30651332

Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.

Seamus P Caragher1, Jack M Shireman1, Mei Huang1, Jason Miska1, Fatemeh Atashi1, Shivani Baisiwala1, Cheol Hong Park1, Miranda R Saathoff1, Louisa Warnke1, Ting Xiao1, Maciej S Lesniak1, C David James1, Herbert Meltzer2, Andrew K Tryba3, Atique U Ahmed4.   

Abstract

Glioblastoma (GBM) is one of the most aggressive and lethal tumor types. Evidence continues to accrue indicating that the complex relationship between GBM and the brain microenvironment contributes to this malignant phenotype. However, the interaction between GBM and neurotransmitters, signaling molecules involved in neuronal communication, remains incompletely understood. Here we examined, using human patient-derived xenograft lines, how the monoamine dopamine influences GBM cells. We demonstrate that GBM cells express dopamine receptor 2 (DRD2), with elevated expression in the glioma-initiating cell (GIC) population. Stimulation of DRD2 caused a neuron-like hyperpolarization exclusively in GICs. In addition, long-term activation of DRD2 heightened the sphere-forming capacity of GBM cells, as well as tumor engraftment efficiency in both male and female mice. Mechanistic investigation revealed that DRD2 signaling activates the hypoxia response and functionally alters metabolism. Finally, we found that GBM cells synthesize and secrete dopamine themselves, suggesting a potential autocrine mechanism. These results identify dopamine signaling as a potential therapeutic target in GBM and further highlight neurotransmitters as a key feature of the pro-tumor microenvironment.SIGNIFICANCE STATEMENT This work offers critical insight into the role of the neurotransmitter dopamine in the progression of GBM. We show that dopamine induces specific changes in the state of tumor cells, augmenting their growth and shifting them to a more stem-cell like state. Further, our data illustrate that dopamine can alter the metabolic behavior of GBM cells, increasing glycolysis. Finally, this work demonstrates that GBM cells, including tumor samples from patients, can synthesize and secrete dopamine, suggesting an autocrine signaling process underlying these results. These results describe a novel connection between neurotransmitters and brain cancer, further highlighting the critical influence of the brain milieu on GBM.
Copyright © 2019 the authors 0270-6474/19/391982-12$15.00/0.

Entities:  

Keywords:  cancer stem cell; cellular plasticity; dopamine; glioblastoma

Mesh:

Substances:

Year:  2019        PMID: 30651332      PMCID: PMC6507082          DOI: 10.1523/JNEUROSCI.1589-18.2018

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

1.  Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat.

Authors:  Ming Yang; Natalie D Stull; Mathew A Berk; Evan Y Snyder; Lorraine Iacovitti
Journal:  Exp Neurol       Date:  2002-09       Impact factor: 5.330

2.  Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission.

Authors:  Stan B Floresco; Anthony R West; Brian Ash; Holly Moore; Anthony A Grace
Journal:  Nat Neurosci       Date:  2003-09       Impact factor: 24.884

3.  Dopamine modulates cell cycle in the lateral ganglionic eminence.

Authors:  Nobuyo Ohtani; Tomohide Goto; Christian Waeber; Pradeep G Bhide
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

4.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

5.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Authors:  Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  Hypoxia is important in the biology and aggression of human glial brain tumors.

Authors:  Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

7.  Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

Authors:  Günter U Höglinger; Pamela Rizk; Marie P Muriel; Charles Duyckaerts; Wolfgang H Oertel; Isabelle Caille; Etienne C Hirsch
Journal:  Nat Neurosci       Date:  2004-06-13       Impact factor: 24.884

8.  Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone.

Authors:  Sarah A Baker; K Adam Baker; Theo Hagg
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

9.  Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.

Authors:  Rossella Galli; Elena Binda; Ugo Orfanelli; Barbara Cipelletti; Angela Gritti; Simona De Vitis; Roberta Fiocco; Chiara Foroni; Francesco Dimeco; Angelo Vescovi
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  29 in total

1.  The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.

Authors:  Kruttika Bhat; Mohammad Saki; Erina Vlashi; Fei Cheng; Sara Duhachek-Muggy; Claudia Alli; Garrett Yu; Paul Medina; Ling He; Robert Damoiseaux; Matteo Pellegrini; Nathan R Zemke; Phioanh Leia Nghiemphu; Timothy F Cloughesy; Linda M Liau; Harley I Kornblum; Frank Pajonk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-01       Impact factor: 11.205

2.  Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Authors:  Isabel Arrillaga-Romany; Yazmin Odia; Varun V Prabhu; Rohinton S Tarapore; Krystal Merdinger; Martin Stogniew; Wolfgang Oster; Joshua E Allen; Minesh Mehta; Tracy T Batchelor; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

3.  Prognostic Neurotransmitter Receptors Genes Are Associated with Immune Response, Inflammation and Cancer Hallmarks in Brain Tumors.

Authors:  Yuri Belotti; Serenella Tolomeo; Rongjun Yu; Wan-Teck Lim; Chwee Teck Lim
Journal:  Cancers (Basel)       Date:  2022-05-21       Impact factor: 6.575

4.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 5.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.

Authors:  Plabon Kumar Das; Suja Pillai; Md Abdur Rakib; Jahan Ara Khanam; Vinod Gopalan; Alfred K Y Lam; Farhadul Islam
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

6.  Separate and not equal: sex differences in JAM-A tumor suppression in glioblastoma.

Authors:  Jack M Shireman; Atique U Ahmed
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

7.  De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.

Authors:  Jack M Shireman; Fatemeh Atashi; Gina Lee; Eunus S Ali; Miranda R Saathoff; Cheol H Park; Sol Savchuk; Shivani Baisiwala; Jason Miska; Maciej S Lesniak; C David James; Roger Stupp; Priya Kumthekar; Craig M Horbinski; Issam Ben-Sahra; Atique U Ahmed
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

8.  Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma.

Authors:  Kruttika Bhat; Mohammad Saki; Fei Cheng; Ling He; Le Zhang; Angeliki Ioannidis; David Nathanson; Jonathan Tsang; Steven J Bensinger; Phioanh Leia Nghiemphu; Timothy F Cloughesy; Linda M Liau; Harley I Kornblum; Frank Pajonk
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 11.816

9.  Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.

Authors:  Ling He; Kruttika Bhat; Angeliki Ioannidis; Le Zhang; Nhan T Nguyen; Joshua E Allen; Phioanh Leia Nghiemphu; Timothy F Cloughesy; Linda M Liau; Harley I Kornblum; Frank Pajonk
Journal:  Radiother Oncol       Date:  2021-06-05       Impact factor: 6.901

Review 10.  Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets?

Authors:  Arely Rosas-Cruz; Nohemí Salinas-Jazmín; Marco A Velasco- Velázquez
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.